Induction chemotherapy followed by radical local therapy for locally advanced non-small cell lung cancer

Seminars in Surgical Oncology

Volumn 21, Issue 2, 2003, Pages 111-121

  Wendland, Merideth M M ^a   Sause, William T ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b LDS HOSPITAL   (United States)

Author keywords

Chemotherapy; Combined modality; Locally advanced; Lung cancer; Radiation

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; MITOMYCIN; NAVELBINE; PACLITAXEL; TRASTUZUMAB; VINBLASTINE; VINDESINE;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; ESOPHAGITIS; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; REVIEW; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0141927960     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.10028     Document Type: Review

References (77)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
3. Mountain CF: Prognostic implications of the International Staging System for Lung Cancer. Semin Oncol 1988;15:236-245.
4. Choi NC, Doucette JA: Improved survival of patients with unresectable non-small-cell bronchogenic carcinoma by an innovated high-dose en-bloc radiotherapeutic approach. Cancer 1981;48:101-109.
5. Perez CA, Pajak TF, Rubin P, et al: Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987;59:1874-1881.
6. Arriagada R, Le Chevalier T, Rekacewicz C, et al: Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC): late analysis of a French randomized trial [Abstract]. Proc Am Soc Clin Oncol 1997;16.
7. Hall EJ: "Radiobiology for the radiologist." 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2000.
8. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
9. Robinson LA, Wagner H Jr, Ruckdeschel JC: Treatment of stage IIIA non-small cell lung cancer. Chest 2003;123(1 Suppl):202S-220S.
10. Jett JR, Scott WJ, Rivera MP, Sause WT: Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 2003;123(1 Suppl): 221S-225S.
11. Greene FL, Page DL, Fleming ID, et al: "AJCC Cancer Staging Manual." 6th ed. New York: Springer; 2002.
12. Shields TW: The significance of ipsilateral mediastinal lymph node metastasis (N2 disease) in non-small cell carcinoma of the lung. A commentary. J Thorac Cardiovasc Surg 1990;99:48-53.
13. Rusch VW: Surgical treatment of patients with N2 disease. Semin Radiat Oncol 1996;6:76-85.
14. , Pearson FG, DeLarue NC, Ilves R, et al: Significance of positive mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982;83:1-11.
15. Martini N, Flehinger BJ, Zaman MB, Beattie EJ Jr: Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 1983;198:386-397.
16. , Astudillo J, Conill C: Role of postoperative radiation therapy in stage IIIa non-small cell lung cancer. Ann Thorac Surg 1990;50:618-623.
17. Sawyer TE, Bonner JA, Gould PM, et al: The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer 1997;80:1399-1408.
18. Choi NC, Grillo HC, Gardiello M, et al: Basis for new strategies in postoperative radiotherapy of bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1980;6:31-35.
19. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352(9124):257-263.
20. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311(7010):899-909.
21. Scott C, Sause WT, Byhardt R, et al: Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. Lung Cancer 1997;17(Suppl):S59-S74.
22. Komaki R, Scott CB, Byhardt R, et al: Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four Radiation Therapy Oncology Group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1998;42:263-267.
23. Joss RA, Cavalli F, Goldhirsch A, et al: New agents in non-small cell lung cancer. Cancer Treat Rev 1984;11:205-236.
24. Zinner RG, Kim J, Herbst RS: Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 2002;37:17-27.
25. Bunn PA Jr, Franklin W: Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002;29(5 Suppl 14):38-44.
26. Komaki R, Lee JS, Kaplan B, et al: Randomized phase III study of chemoradiation ± amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC) [Abstract]. Proc Am Soc Clin Oncol 2001;20:325a: 1298.
27. Byhardt RW, Scott C, Sause WT, et al: Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998;42:469-478.
28. Byhardt RW: Toxicities in RTOG combined-modality trials for inoperable non-small-cell lung cancer. Oncology (Huntingt) 1999;13(10 Suppl 5):116-120.
29. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-945.
30. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
31. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
32. Sause W, Kolesar P, Taylor S IV, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364.
33. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423.
34. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 1994;10(Suppl 1): S239-S244.
35. Cullen MH, Billingham LJ, Woodroffe CM et al: Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 1. results of a randomised trial in patients with localised, inoperable disease [Abstract]. Lung Cancer 1997;18(suppl 1):5:10.
36. Mattson K, Holsti LR, Holsti P, et al: Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988;24:477-482.
37. Crino L, Latini P, Meacci M, et al: Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 1993;4:847-851.
38. Planting A, Helle P, Drings P, et al: A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. Ann Oncol 1996;7:139-144.
39. Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 1991;115:681-686.
40. Marino P, Preatoni A, Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995;76:593-601.
41. Pritchard RS, Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: a meta-analysis. Ann Intern Med 1996;125:723-729.
42. Ritter MA: Determination of tumor kinetics: strategies for the delivery of radiation and chemotherapy. Curr Opin Oncol 1999;11:177-182.
43. Belani CP: Multimodality management of regionally advanced non-small-cell lung cancer. Semin Oncol 1993;20:302-314.
44. Schaake-Koning C, vanden Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
45. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer, J Clin Oncol 1999;17:2692-2699.
46. Curran W Jr, Scott C, Langer C, et al: Phase III comparison of sequential vs. concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 [Abstract]. Proc Am Soc Clin Oncol 2000;19:484a:1891.
47. Siegenthaler MP, Pisters KM, Merriman KW, et al: Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 2001;71:1105-1111.
48. Martin J, Ginsberg RJ, Abolhoda A, et al: Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001;72:1149-1154.
49. Martin J, Ginsberg RJ, Venkatraman ES, et al: Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 2002;20:1989-1995.
50. Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
51. Roth JA, Atkinson EN, Fossella F, et al: Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6.
52. Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158.
53. Rosell R, Gomez-Codina J, Camps C, et al: Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26:7-14.
54. Pass HI, Pogrebniak HW, Steinberg SM, et al: Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992;53:992-998.
55. Rusch VW, Albain KS, Crowley JJ, et al: Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg 1993;105:97-104.
56. Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-1892.
57. Rusch VW, Giroux DJ, Kraut MJ, et al: Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001;121:472-483.
58. Albain KS, Scott CB, Rusch VR, Turrisi AT, Shepherd FA, Smith C, Gandara DR, Johnson DH, Green MR, Miller RC. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Initial results from intergroup trial 0139 (RTOG 93-09) [Abstract]. Proc Am Soc Clin Oncol 2003;2497.
59. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
60. Paesmans M, Sculier JP, Lecomte J, et al: Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-533.
61. Wemer-Wasik M, Scott C, Cox JD, et al: Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LANSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000;48:1475-1482.
62. Byhardt RW, Scott CB, Ettinger DS, et al: Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small cell lung cancer. Cancer 1995;75:2337-2344.
63. Sederholm C: Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG) [Abstract]. Proc Am Soc Clin Oncol 2002;21:291a:1162.
64. Lilenbaum RC, Herndon J, List M, et al: Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness [Abstract]. Proc Am Soc Clin Oncol 2002;21:1a:2.
65. Georgoulias V, Ardavanis A, Agelidou M, et al: Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non-small cell lung cancer (NSCLC) [Abstract]. Proc Am Soc Clin Oncol 2002;21:291a:1163.
66. Masuda N, Fukuoka M, Negoro S, et al: Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study [Meeting Abstract]. Proc Am Soc Clin Oncol 2002;18:459a:1774.
67. Vokes EE, Herndon JE 2nd, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-4198.
68. Roach M 3rd, Gandara DR, Yuo HS, et al: Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 1995;13:2606-2612.
69. Van Zandwijk N, Smit EF, Kramer GW, et al: Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000;18:2658-2664.
70. Pisters KM, Ginsberg RJ, Giroux DJ, et al: Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000;119:429-439.
71. Emami B, Lyman J, Brown A, et al: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122.
72. Graham MV, Purdy JA, Emami B, et al: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-329.
73. Hodapp N, Boesecke R, Schlegel W, et al: Three-dimensional treatment planning for conformation therapy of a bronchial carcinoma. Radiother Oncol 1991;20:245-249.
74. Vijayakumar S, Myrianthopoulos LC, Rosenberg I, et al: Optimization of radical radiotherapy with beam's eye view techniques for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1991;21:779-788.
75. Emami B, Purdy JA, Manolis J, et al: Three-dimensional treatment planning for lung cancer. Int J Radiat Oncol Biol Phys 1991;21:217-227.
76. Saunders M, Dische S, Barrett A, et al: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350(9072): 161-165.
77. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S: Hyperfractionated radiation therapy with or without concurrent low-dose, daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-1070.